{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:20:13Z","timestamp":1787505613473,"version":"build-2736575974"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients who received oxaliplatin between January 2017 and December 2023 were retrospectively analyzed. Among them, 53 received 100\u2005mg of hydrocortisone as a preventive measure when the cumulative oxaliplatin dose exceeded 400\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or if they experienced a treatment interruption of &gt;8 weeks. We compared the incidence and severity of hypersensitivity reactions, as well as cumulative oxaliplatin dose, between patients who received routine premedication only (the Routine group) and those who received additional hydrocortisone prophylaxis (the Prophylaxis group).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 370 patients were included in the study. Hypersensitivity reactions occurred in 23 patients (18 in the Routine group and 5 in the Prophylaxis group), with a significantly higher cumulative dose of oxaliplatin in the Prophylaxis group (644 vs. 1383\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0032). Severe reactions were observed only in the Routine group. Treatment discontinuation owing to hypersensitivity reactions was more common in the Routine group (five patients) than in the Prophylaxis group (one patient).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prophylactic administration of hydrocortisone may promote oxaliplatin treatment continuation. This approach is proposed as a potential strategy for preventing oxaliplatin-induced hypersensitivity reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251372177","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:04:47Z","timestamp":1757347487000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: A retrospective study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-6327","authenticated-orcid":false,"given":"Maho","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"},{"name":"Department of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3445-9595","authenticated-orcid":false,"given":"Masato","family":"Komuro","sequence":"additional","affiliation":[{"name":"Japan Health Research Promotion Bureau, Section of Informatics Platform for Medical Research and Collaboration, Department of Medical Informatics, Bureau of System Infrastructure Development, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-1061","authenticated-orcid":false,"given":"Satoshi","family":"Numazawa","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Benson AB Hunt S Nurkin S. Rectal Cancer. NCCN Guidelines for Patients https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/rectal-patient.pdf (2024 accessed 21 April 2025)."},{"key":"e_1_3_3_3_2","unstructured":"Benson AB Hunt S Nurkin S. Colon cancer. NCCN Guidelines for Patients https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/colon-patient.pdf (2024 accessed 21 April 2025)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403108"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02034-3"},{"key":"e_1_3_3_6_2","first-page":"2461","article-title":"Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer","volume":"14","author":"Song Q","year":"2022","unstructured":"Song Q, Cai Y, Guo K, et al. Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. Am J Transl Res 2022; 14: 2461\u20132468.","journal-title":"Am J Transl Res"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3294-9"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-021-2387-1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026520812351"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3727\/096504017X15139039328978"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i38.5427"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0170-6"},{"key":"e_1_3_3_13_2","first-page":"5521","article-title":"Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer","volume":"32","author":"Yanai T","year":"2012","unstructured":"Yanai T, Iwasa S, Hashimoto H, et al. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer. Anticancer Res 2012; 32: 5521\u20135526.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2437-5"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S94901"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603048"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0308"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.11.013"},{"key":"e_1_3_3_19_2","unstructured":"Pharmacia and Upjohn Company LLC. SOLU-CORTEF\u00ae - hydrocortisone sodium succinate for injection USP https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=641 (accessed 21 April 2025)."},{"key":"e_1_3_3_20_2","unstructured":"ELPLAT I.V. INFUSION SOLUTION 50\u2005mg 100\u2005mg 200\u2005mg. Guide for appropriate use of medication https:\/\/www.takata-seiyaku.co.jp\/medical\/region\/hpj79b0000005ihm-att\/ELP-IS01(2).pdf (accessed 10 July 2025)."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08932-2"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08877-y"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.8.210"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0106"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2012.13.4.1209"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251372177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:39Z","timestamp":1777689099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251372177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":24,"alternative-id":["10.1177\/10781552251372177"],"URL":"https:\/\/doi.org\/10.1177\/10781552251372177","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"10781552251372177"}}